O.160 16 or 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with HCV genotype 2 or 3 and bridging fibrosis or cirrhosis: Results from a large, randomised multinational study (ACCELERATE)

✍ Scribed by S. Zeuzem; S. Pappas; L. Nyberg; S. Greenbloom; A. Gibas; B. Bacon; E. Godofsky; H. Harley; J. Bronowicki; A. Lin; A. Soman; M. Shiffman

• Book ID: 117770192
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 143 KB
• Volume: 36
• Category: Article
• ISSN: 1386-6532
• DOI: 10.1016/s1386-6532(06)80151-4